Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNP023 in IgA nephropathy – dose–response on proteinuria
CTR20191211Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Iptacopan in IgA nephropathy (IgAN), sponsored by Novartis. Started Jul 2019; status: completed.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20191211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191211.